[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Merus N.V. Common Shares (MRUS)
Merus N.V. Common Shares (MRUS) price hits a 52-week high following Genmab acquisition news and positive clinical trial results for petosemtamab. Social media buzz highlights 13F filings and collaboration news.
About Merus N.V. Common Shares
Merus N.V. is a biotechnology company focused on developing antibody-based therapeutics for cancer.
Merus N.V. Common Shares uses the ticker $MRUS for trading. Listed in the Stocks category within the Healthcare sectors.
Insights
- Merus N.V. Common Shares (MRUS) trading volume is up XXXXX% from the previous week.
- Merus N.V. Common Shares (MRUS) social dominance is up 1066.67% from the previous week.
- Merus N.V. Common Shares Price hit a 52-Week high of $XXXXX for the hour
- Merus N.V. Common Shares Price hit an all time of $XXXXX for the hour
Price: $XXXXX
Price 24-Hour Time-Series Raw Data
The stock price has surged to a 52-week high, driven by the acquisition news from Genmab at a significant premium and positive clinical trial results for its lead drug candidate, petosemtamab. Recent social media activity shows increased mentions in 13F filings and collaboration news, reflecting strong market confidence.
24-Hour: -XXXX% 7-Day: XXXX% 30-Day: XXXX%
1-Year High: $XXXXX on 2025-12-10
1-Year Low: $XXXXX on 2025-04-08
AltRank: XXXXX
AltRank 24-Hour Time-Series Raw Data
Merus N.V. Common Shares (MRUS) is currently AltRank #1,119 based on combined combined social and market metrics
Daily Average: XXX
X Week: XXX +112
X Month: XXX -XXX
X Months: XXX +103
X Year: XXX +283
1-Year High: XXXXX on 2025-08-12
1-Year Low: XX on 2025-05-25
Galaxy Score: XXXXX
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XX
X Week: XX no change
X Month: XX -XX
X Months: XX -XX
X Year: XX -XX
1-Year High: XX on 2025-07-10
1-Year Low: XX on 2025-09-19
Engagements: XXXXX (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XXXXXX
X Week: XXXXX -XX%
X Month: XXXXXXX -XXXX%
X Months: XXXXXXXXX +66%
X Year: XXXXXXXXX -XX%
1-Year High: XXXXXXX on 2025-09-29
1-Year Low: XX on 2025-12-06
Engagements by network (24h): X: XXXXX
Mentions: XX (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XXX
X Week: XXX -XX%
X Month: XXX -XX%
X Months: XXXXX +100%
X Year: XXXXX +420%
1-Year High: XXXXX on 2025-07-10
1-Year Low: X on 2025-12-07
Mentions by network (24h): X: XXX
Creators: XX (24h)
Creators 24-Hour Time-Series Raw Data
XX unique social accounts have posts mentioning Merus N.V. Common Shares (MRUS) in the last XX hours which is down XX% from XX in the previous XX hours
Daily Average: XX
X Week: XX -X%
X Month: XXX -XX%
X Months: XXXXX +77%
X Year: XXXXX +586%
1-Year High: XXX on 2025-09-29
1-Year Low: X on 2025-12-07
The most influential creators that mention Merus N.V. Common Shares in the last XX hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @NightOwlBiotech | X | XXXXX | X | XX |
| @seedytx19 | X | XXXXX | X | XX |
| @BuyTheUgly | X | XX | X | XX |
| @bryan_plat47867 | X | XXX | X | XX |
| @Tickeron | X | XXXXXX | X | XX |
| @AponiaAnalytics | X | XXXXX | X | XX |
| @EpicStockAlert | X | XX | X | XX |
| @BiopharmIQ | X | XXXXXX | X | XX |
| @Formal49019 | X | XX | X | X |
| @Sophia_Cormicks | XX | XX | X | X |
Sentiment: XX%
Sentiment 24-Hour Time-Series Raw Data
Current Value: XX%
Daily Average: XX%
X Week: XX% -X%
X Month: XX% -XX%
X Months: XX% -XX%
X Year: XX% -XX%
1-Year High: XXX% on 2025-01-26
1-Year Low: XX% on 2024-12-29
Most Supportive Themes:
- Acquisition by Genmab: (30%) Genmab's agreement to acquire Merus for $X billion, with multiple rounds of bidding and a significant premium, indicates strong investor confidence in Merus's pipeline and potential.
- Promising Drug Trial Data: (25%) Positive results for petosemtamab in head and neck cancer, showing a high response and survival rate, presented at ASCO 2025, have driven analyst upgrades and stock surges.
- Analyst Upgrades and Price Targets: (20%) Analysts have raised their price targets for Merus, citing the promising clinical trial data and the potential of its drug candidates, further boosting investor sentiment.
Most Critical Themes:
- Risk Factor Disclosures: (15%) Merus has flagged rising net losses, expanded clinical and commercialization risks, and heavy reliance on partners, alongside new uncertainties from pending transactions.
- Regulatory and Market Acceptance Challenges: (10%) The company faces heightened challenges in intellectual property, regulatory approvals, supply chain, and market acceptance, as well as warnings on side effects and patient enrollment.
Social Dominance: XXXXXXX%
Social Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXXXX%
Daily Average: XXXXX%
X Week: XXXXX% +0.0096%
X Month: XXXXX% +0.0066%
X Months: XXXXX% -XXXXXX%
X Year: XXXXX% -XXXXXX%
1-Year High: XXXXX% on 2025-07-10
1-Year Low: XXXXXX% on 2025-12-07
Market Dominance: XXXXXXX%
Market Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXXXX%
Daily Average: X%
1-Year High: XXXXX% on 2025-03-31
1-Year Low: XXXXXXX% on 2025-02-14
Market Cap: $XXXXXXXXXXXXX
Market Cap 24-Hour Time-Series Raw Data
Current Value: $XXXXXXXXXXXXX
Daily Average: $XXXXXXXXXXXXX
X Week: $XXXXXXXXXXXXX +$0.63%
X Month: $XXXXXXXXXXXXX +$1.30%
X Months: $XXXXXXXXXXXXX +$80%
X Year: $XXXXXXXXXXXXX +$148%
1-Year High: $XXXXXXXXXXXXX on 2025-12-10
1-Year Low: $XXXXXXXXXXXXX on 2025-04-08
Top Merus N.V. Common Shares Social Posts
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"#Options traders: Info memos from today and yesterday: $MRUS $ARBK $ARBK1 $IRMD $ATMC $OCTF $HPP1 $TEO1 $NOW $1NOW $2NOW $4SPX $HSII $SCS $HNI1 $ODP $WTP1 $GVLU $XC $MSFU $GGLL $AVL $TSLL $2TSLL $AMZU $NVDU $ELIL $APPU $FAS $DUSL $DFEN $SPUU $HIBL $TECL $2TECL and $LMBO. Find details at:"
X Link @Options_Edu 2025-12-11T01:26Z 12.3K followers, XXX engagements
"$MRUS Guys Don't miss the Target price for Next Week. 📊➡"
X Link @JoytiToma 2025-12-10T13:30Z XX followers, XX engagements
"Of course the second I sold my $MRUS at $XXXXX it skyrockets Im actually smooth brain 🤡 Biggest L of 2025 I hate myself"
X Link @RebeccaH33337 2025-12-10T12:31Z X followers, XX engagements
"Event-Driven News: $FNMA $FMCC $COLD $AVDL $MRUS $MGM $IAC $GPRK $ALTI $INTC #FirstBrands $ODP $HSII $HSIC #Mergers #Acquisitions #EventDriven *FIFTH THIRD TO ACQUIRE FANNIE MAE DUS BUSINESS LINE *ANCORA PUSHES AMERICOLD TO WEIGH OPTIONS INCLUDING BREAKUP AVDL and MRUS get hsr approval Mgm Resorts International Iac Inc.: SCHEDULE 13D/A *GeoPark: Communicated Belief Parex's Offer of $9/Shr Undervalues Co From Outset of Negotiations *GeoPark Board: Any Credible or Constructive Engagement Going Forward Would Require Revised Proposal Beginning in Double-digits *AlTi Global Has Received"
X Link @Off_The_Tape 2025-12-10T11:48Z XXX followers, 1211 engagements